Nl-Fr

View abstract

This abstract is assigned to session BGS: Belgian Glaucoma Society
Presentation typeOB - oral
TitleThe effect of a single, preoperative, intracameral administration of bevacizumab (Avastin®) on trabeculectomy outcome: A prospective, randomized, double-blinded, placebo-controlled trial.
PurposeTo investigate the effect of a single, preoperative administration of bevacizumab (Avastin®) in terms of clinical outcome following trabeculectomy in patients with either primary open-angle glaucoma (POAG) or normal tension glaucoma (NTG).
Methods141 medically uncontrolled glaucoma patients who were scheduled for primary trabeculectomy were included in this prospective, randomized, double-blinded and placebo-controlled study. Patients were divided into POAG and NTG, which were then randomized to receive 50 µl of either bevacizumab (25 mg/ml) or placebo peroperatively. NTG patients also received mitomycin C. The target intraocular pressure (IOP) range was between 6 and 18 mmHg for POAG and between 6 and 14 mmHg for NTG. Absolute success was defined as meeting the target IOP at 6 month of follow-up without IOP-lowering medications or postoperative interventions. Qualified success was defined as meeting the target IOP at month 6 with or without either IOP-lowering medications and/or postoperative surgical interventions.
ResultsAbsolute success in the bevacizumab group was 83% compared to 59% in the placebo group (p=0.003, Odds Ratio (OR) 3.3, confidence interval (CI) 1.4-7.9). Qualified success was 99% in the bevacizumab group versus 94% in the placebo group (not significant, OR 4, CI 0.3-201). Needlings were significantly less frequent in the bevacizumab group as compared to the placebo group, respectively in 11% versus 32% (p=0.004). Complication rates were comparable in both groups.
ConclusionA single preoperative intracameral administration of bevacizumab was associated with increased absolute success rates and reduced need for postoperative interventions.
Author 1
Last nameVANDEWALLE
InitialsE
DepartmentUZLeuven
CityLeuven
Author 2
Last nameZEYEN
InitialsT
DepartmentUZLeuven
CityLeuven
Author 3
Last nameVAN BERGEN
InitialsT
DepartmentUZLeuven
CityLeuven
Author 4
Last nameSPIELBERG
InitialsL
DepartmentRotterdam Eye Hospital
CityRotterdam
Author 5
Last nameSTALMANS
InitialsI
DepartmentUZLeuven
CityLeuven
top ^